Paul K. Paik, MD is a medical oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) who specializes in the treatment of lung cancers.  He is an Associate Attending Physician in the Thoracic Oncology Service at MSKCC, an Associate Professor of Medicine at Weill Cornell Medical College, and serves as the Clinical Director for the Thoracic Oncology Program at MSKCC. Dr. Paik’s research focuses on squamous cell lung cancer, targeted therapeutics, and translational therapies aimed at the metastatic process.

Michael Thomas is the Head of the Department of Thoracic Oncology at Thoraxklinik, University Hospital of Heidelberg and on the Board of Directors at the National Center for Tumor Diseases. Prior to taking over the position at Heidelberg in 2005, he was a full professor at the University Hospital of Münster. Professor Thomas is strongly dedicated to the conception, conduction, and coordination of clinical trials and biomarker exploration in the field of thoracic oncology. Chairing the German Lung Cancer Cooperative Group, he designed and conducted large-scale phase III trials in the trimodality treatment setting of non-small cell lung cancer; here, he has been awarded with the John Mendelsohn – Clinical Trial Award of the German Cancer Society. Current translational research activities focus on the assessment of molecular features and prerequisites of the tumor microenvironment indicating predictive and prognostic impact in the locally advanced and metastatic treatment setting.

Robert (Rob) Coleman is Emeritus Professor of Medical Oncology in the Department of Oncology and Metabolism at the University of Sheffield, UK. He graduated in medicine from King’s College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991; he was instrumental in developing clinical cancer research in Sheffield and established an internationally respected bone oncology research team in the city. Professor Coleman has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network. He has published over 450 peer-reviewed manuscripts and numerous book chapters, and is a Past-President of the Cancer and Bone Society and the founding editor of Journal of Bone Oncology.

During 2014–2019, Professor Coleman was a part-time Medical Director for the global independent medical education provider, prIME Oncology, developing and delivering both live and online educational activities for oncologists and other providers of cancer care. Since retiring from his formal position at the university in 2017, he remains active in research, lectures on his areas of expertise around the world, and provides consultancy to a medical education company as well as a range of pharma and biotech companies developing new oncology treatments.